This article is from the source 'guardian' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.theguardian.com/australia-news/2022/jul/06/pfizer-vaccines-that-target-omicron-variant-pass-first-step-to-approval-in-australia
The article has changed 3 times. There is an RSS feed of changes available.
| Version 0 | Version 1 |
|---|---|
| Pfizer vaccines that target Omicron variant pass first step to approval in Australia | Pfizer vaccines that target Omicron variant pass first step to approval in Australia |
| (3 months later) | |
| The TGA’s ‘provisional determination’ for two vaccines comes as BA.4 and BA.5 subvariants drive new wave of Covid cases | The TGA’s ‘provisional determination’ for two vaccines comes as BA.4 and BA.5 subvariants drive new wave of Covid cases |
| Two vaccines that specifically target the Omicron variant have been granted “provisional determination” by Australia’s drugs regulator, the first step in a process for getting the vaccines approved for use. | Two vaccines that specifically target the Omicron variant have been granted “provisional determination” by Australia’s drugs regulator, the first step in a process for getting the vaccines approved for use. |
| It comes as the BA.4 and BA.5 subvariants of Omicron drive a new wave of cases, prompting premiers to warn of increasing hospitalisations and deaths, and renewed calls to the public to wear masks in crowded indoor spaces. | It comes as the BA.4 and BA.5 subvariants of Omicron drive a new wave of cases, prompting premiers to warn of increasing hospitalisations and deaths, and renewed calls to the public to wear masks in crowded indoor spaces. |
| While existing vaccines are very effective at preventing hospitalisation with and death from BA.4 and BA.5, they are less effective at stopping transmission and symptoms. | While existing vaccines are very effective at preventing hospitalisation with and death from BA.4 and BA.5, they are less effective at stopping transmission and symptoms. |
| The surge in cases has put pressure on the Australian Technical Advisory Group on Immunisation (Atagi), which was meeting on Wednesday to consider whether fourth doses of existing vaccines should be recommended for the wider population as cases surge. | The surge in cases has put pressure on the Australian Technical Advisory Group on Immunisation (Atagi), which was meeting on Wednesday to consider whether fourth doses of existing vaccines should be recommended for the wider population as cases surge. |
| One of the challenges Atagi faces in making its decision is that for healthy people, three vaccine doses are very effective at preventing severe disease and death, and this combined with immunity from Covid-19 infections may mean approving a fourth dose for everyone is not effective. | One of the challenges Atagi faces in making its decision is that for healthy people, three vaccine doses are very effective at preventing severe disease and death, and this combined with immunity from Covid-19 infections may mean approving a fourth dose for everyone is not effective. |
| The wider concern may be ensuring booster doses are accessible for the most vulnerable, with elderly and under-vaccinated people with comorbidities overrepresented in Covid deaths. | The wider concern may be ensuring booster doses are accessible for the most vulnerable, with elderly and under-vaccinated people with comorbidities overrepresented in Covid deaths. |
| Atagi will also be considering whether it is worth waiting for better, more targeted boosters on the horizon, such as Pfizer’s. | Atagi will also be considering whether it is worth waiting for better, more targeted boosters on the horizon, such as Pfizer’s. |
| However, the two Pfizer vaccines granted provisional determination on Wednesday target the spike protein of the Omicron BA.1 variant of concern. Data is still being collected by Pfizer on how effective the vaccines might be against the BA.4 and BA.5 Omicron subvariants becoming dominant in Australia. | However, the two Pfizer vaccines granted provisional determination on Wednesday target the spike protein of the Omicron BA.1 variant of concern. Data is still being collected by Pfizer on how effective the vaccines might be against the BA.4 and BA.5 Omicron subvariants becoming dominant in Australia. |
| Prof Ugur Sahin, the chief executive of BioNTech which developed the vaccine in conjunction with Pfizer, said: “Omicron has newly evolving sublineages that have outcompeted BA.1 and exhibit a trend of increasing potential for immune escape. | Prof Ugur Sahin, the chief executive of BioNTech which developed the vaccine in conjunction with Pfizer, said: “Omicron has newly evolving sublineages that have outcompeted BA.1 and exhibit a trend of increasing potential for immune escape. |
| “We will therefore remain vigilant and are prepared to rapidly adapt our Omicron-adapted vaccine candidates to emerging sublineages if epidemiological and laboratory data suggest.” | “We will therefore remain vigilant and are prepared to rapidly adapt our Omicron-adapted vaccine candidates to emerging sublineages if epidemiological and laboratory data suggest.” |
| Sign up to receive an email with the top stories from Guardian Australia every morning | Sign up to receive an email with the top stories from Guardian Australia every morning |
| Sign up to receive an email with the top stories from Guardian Australia every morning | Sign up to receive an email with the top stories from Guardian Australia every morning |
| Provisional determination is an early step in the vaccine approval process. To grant provisional determination, the Therapeutic Goods Administration would have required preliminary clinical data and evidence from Pfizer of a plan to submit more comprehensive clinical data down the track. It also would have needed to see a strong argument for why the vaccines are needed. | Provisional determination is an early step in the vaccine approval process. To grant provisional determination, the Therapeutic Goods Administration would have required preliminary clinical data and evidence from Pfizer of a plan to submit more comprehensive clinical data down the track. It also would have needed to see a strong argument for why the vaccines are needed. |
| Now that the TGA has granted provisional determination, Pfizer can apply for “provisional registration” of the vaccine. Pfizer has six months to do this, and will need to submit further data to the TGA from human trials about how the treatment works and its safety. | Now that the TGA has granted provisional determination, Pfizer can apply for “provisional registration” of the vaccine. Pfizer has six months to do this, and will need to submit further data to the TGA from human trials about how the treatment works and its safety. |
| Email: sign up for our daily morning and afternoon email newsletters | |
| App: download the free app and never miss the biggest stories, or get our weekend edition for a curated selection of the week's best stories | App: download the free app and never miss the biggest stories, or get our weekend edition for a curated selection of the week's best stories |
| Social: follow us on YouTube, Facebook, Instagram, Twitter or TikTok | Social: follow us on YouTube, Facebook, Instagram, Twitter or TikTok |
| Podcast: listen to our daily episodes on Apple Podcasts, Spotify or search "Full Story" in your favourite app | Podcast: listen to our daily episodes on Apple Podcasts, Spotify or search "Full Story" in your favourite app |
| Once the TGA has scrutinised the data, and if it is satisfied with it, it may grant Pfizer “provisional approval” for the vaccines to be used in Australia. Further data must be collected and given to the TGA even if this occurs, and the government will also await recommendations from Atagi. | Once the TGA has scrutinised the data, and if it is satisfied with it, it may grant Pfizer “provisional approval” for the vaccines to be used in Australia. Further data must be collected and given to the TGA even if this occurs, and the government will also await recommendations from Atagi. |
| In a statement, the TGA said it would “undertake a rigorous assessment of the safety, efficacy and quality of these vaccines with the highest priority”. | In a statement, the TGA said it would “undertake a rigorous assessment of the safety, efficacy and quality of these vaccines with the highest priority”. |